Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was incorporated in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.
Frequently asked questions
What sector does Pharmena S.A. (PHR) operate in?
Pharmena S.A. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pharmena S.A. (PHR) current stock price?
As of the latest data, Pharmena S.A. stock price is PLN 3.18, with a previous close of PLN 3.10. Pharmena S.A. gained PLN 0.08 in the last trading session, representing a 2.58% increase.
What is Pharmena S.A. (PHR) current market capitalization?
Pharmena S.A. market cap is approximately 35.42 million.
What is Pharmena S.A. (PHR) Earnings Per Share (EPS)?
The trailing EPS is -PLN 0.25.
What is Pharmena S.A. (PHR) EBITDA?
Pharmena S.A. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -443.00 thousand.
Does Pharmena S.A. (PHR) pay dividends?
No. Pharmena S.A. does not pay a dividend.
What is Pharmena S.A. (PHR) beta (volatility) score?
Pharmena S.A. has a beta of 0.501, indicating lower volatility than the overall market.
